Abstract
Diabetes mellitus is associated with more severe courses of infections and with vaginal dysmicrobia. This article deals with the options in evaluation, treatment, and prophylaxis of gynecological infections.
The new class of antidiabetics - SGLT 2 inhibitors (gliflozins) is also discussed. Gliflozin therapy is associated with slightly elevated risk of dysmicrobia and uroinfection, probably because of its glucosuric effect; these complications, however, respond well to standard treatment and do not tend to recur.
They are likely to reach clinical significance only in women who had suffered from this problem already before gliflozin therapy.